ABC-CT Pre-School Feasibility Study - Trial NCT06413316
Access comprehensive clinical trial information for NCT06413316 through Pure Global AI's free database. This phase not specified trial is sponsored by Yale University and is currently Not yet recruiting. The study focuses on Autism Spectrum Disorder. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Yale University
Timeline & Enrollment
N/A
Aug 01, 2024
Jun 30, 2025
Primary Outcome
N170 Latency to Upright Human Faces,N170 Latency to Upright Human Faces,Oculomotor Index of Gaze to Human Faces (OMI),Oculomotor Index of Gaze to Human Faces (OMI)
Summary
This is a multicenter study that aims to determine whether the EEG and ET experiments studied
 in the ABC-CT Phase 1 and ABC-CT Confirmation studies can be successfully used with
 3-5-year-old children and to determine the viability of these measures as potential
 biomarkers in 3-5-year-old children with ASD. Blood (DNA) samples will be collected from
 participants with ASD and biological parents for future genomic analyses, and raw, processed,
 and analyzed data will be shared to create a community resource accessible for use by all
 qualified investigators. These objectives are designed to advance the long term objective of
 developing promising biomarkers via the FDA Biomarker Qualification Program. This feasibility
 study aims to enroll 25 ASD and 25 TD eligible participants who are 3-5 years old.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06413316
Non-Device Trial